373OResults of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). (23rd October 2018) - Peereboom, D; Nabors, L B; Kumthekar, P; Badruddoja, M; Fink, K; Lieberman, F; Phuphanich, S; Dunbar, E; Walbert, T; Schiff, D; Tran, D D; Ashby, L S; et al.